etravirine has been researched along with HIV Coinfection in 303 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 101 (33.33) | 29.6817 |
| 2010's | 188 (62.05) | 24.3611 |
| 2020's | 14 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KS; Basavapathruni, A; Hamilton, AD; Jorgensen, WL; Ruiz-Caro, J; Tirado-Rives, J | 1 |
| Anderson, KS; Bailey, CM; Basavapathruni, A; Hamilton, AD; Jorgensen, WL; Kim, JT; Ruiz-Caro, J; Wang, L | 1 |
| Chen, CH; Jiang, S; Lai, W; Lee, KH; Lu, H; Qin, B; Tian, X; Xie, L | 1 |
| Azijn, H; Boven, K; de Béthune, MP; Jochmans, D; Kraus, G; Picchio, G; Rimsky, LT; Tirry, I; Van Craenenbroeck, E; Vingerhoets, J | 1 |
| Akonde, A; Calvez, V; Cisse, M; Costagliola, D; Derache, A; Descamps, D; Diarra, B; Katlama, C; Koita, V; Maïga, AI; Malet, I; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Tounkara, A; Verlinden, Y; Wirden, M | 1 |
| Gatanaga, H; Hachiya, A; Hayashida, T; Ode, H; Oka, S; Sato, H | 1 |
| Barbault, F; Chen, CH; Huang, L; Huang, R; Jiang, S; Jiang, X; Lee, KH; Lu, H; Qian, K; Qin, B; Tian, X; Xie, L | 1 |
| Chen, J; Chen, L; Fitch, WL; Fretland, J; Hang, JQ; Harris, SF; Heilek, G; Kertesz, DJ; Klumpp, K; Li, W; Lin, X; Mei, J; Mirzadegan, T; Qiu, Z; Tang, G; Villaseñor, AG; Wang, Z; Yang, M | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Balzarini, J; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| De Clercq, E; Guo, J; Liu, H; Liu, X; Pannecouque, C; Zhang, L | 1 |
| Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
| Gu, SX; Ju, XL; Liu, GY; Lu, HH; Pannecouque, C; Xue, P; Zhang, XL; Zheng, XJ; Zhu, YY | 1 |
| Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Huo, Z; Kang, D; Liu, X; Lu, X; Meng, Q; Pannecouque, C; Tian, Y; Wu, G; Xu, H; Yu, Z; Zhan, P; Zhang, H; Zhou, Z | 1 |
| Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
| Gu, SX; Ju, XL; Liu, GY; Lu, HH; Zhu, YY | 1 |
| Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P | 1 |
| Chen, F; De Clercq, E; Han, S; Pannecouque, C; Sang, Y; Zhuang, C | 1 |
| Cherukupalli, S; De Clercq, E; Jia, R; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, W; Wang, Z; Xie, M; Zhan, P | 1 |
| Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L | 1 |
| Baszczyňski, O; Brumshtein, B; Dračínský, M; Janeba, Z; Jansa, P; Kaiser, MM; Lansdon, EB; Lee, YJ; Prener, L; Stepan, G; Yu, H | 1 |
| Castagna, A; Celesia, BM; Cenderello, G; Corbelli, GM; Ferrara, M; Giammarino, F; Gianotti, N; Maggiolo, F; Martellotta, F; Rusconi, S; Saladini, F; Santoro, MM; Spagnuolo, V; Zazzi, M | 1 |
| Reiss, P; Rijnders, BJA; van der Valk, M; Verburgh, ML; Wit, FWNM | 1 |
| Fletcher, CV; Havens, JP; Podany, AT; Scarsi, KK | 1 |
| Abdi, B; Alloui, C; Assoumou, L; Avettand-Fenoel, V; Beniguel, L; Calvez, V; Costagliola, D; Delaugerre, C; Descamps, D; Ferre, V; Katlama, C; Marcelin, AG; Martinez, E; Montes, B; Nguyen, T; Peytavin, G; Reynes, J; Sayon, S; Soulie, C; Valantin, MA | 1 |
| Berruti, M; Del Puente, F; Di Biagio, A; Riccardi, N | 1 |
| Bonora, S; Calcagno, A; De Benedetto, I; Guastamacchia, G; Trunfio, M | 1 |
| Assoumou, L; Bastard, JP; Beniguel, L; Capeau, J; Costagliola, D; Farabos, D; Fellahi, S; Feve, B; Gibowski, S; Katlama, C; Lamaziere, A; Racine, C | 1 |
| Assoumou, L; Béniguel, L; Bouchaud, O; Capeau, J; Cardon, F; Costagliola, D; Fellahi, S; Gibowski, S; Katlama, C; Kolta, S; Marcelin, AG; Martinez, E; Molina, JM; Peytavin, G; Raffi, F; Reynes, J; Soulié, C; Valantin, MA | 2 |
| Allavena, C; Assoumou, L; Bottero, J; Bouchaud, O; Dudoit, Y; Durand, A; Duvivier, C; Katlama, C; Lê, MP; Marcelin, AG; Montoya Ferrer, A; Palich, R; Peytavin, G; Soulie, C; Tubiana, R; Weiss, L | 1 |
| Hamzah, L; Post, FA | 1 |
| Alvero, CG; Barroso Hofer, C; Costello, DG; Crauwels, HM; Fairlie, L; George, KH; Graham, B; Kiser, JJ; Lypen, K; MacBrayne, CE; Moye, J; Opsomer, M; Reding, CA; Rutstein, RM; Tambuyzer, L; Townley, E; Vanveggel, S; Wiznia, AA; Woot de Trixhe, X | 1 |
| Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A | 1 |
| Calvez, V; Flandre, P; Marcelin, AG | 1 |
| Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N | 1 |
| Challenger, E; Clotet, B; Curran, A; Khoo, S; Miranda, C; Moltó, J; Ribera, E; Santos, JR; Valle, M | 1 |
| Antunes, AMM; Charneira, C; Godinho, ALA; Grilo, J; Jacob, CC; Marques, MM; Martins, IL; Nunes, J; Oliveira, MC; Pereira, SA; Silva, DM; Soto, K | 1 |
| Diphoko, T; Essex, M; Gaseitsiwe, S; Kasvosve, I; Makhema, J; Marlink, R; Moyo, S; Musonda, R; Novitsky, V; Okatch, H; Wainberg, M | 1 |
| Chéret, A; Costagliola, D; Girard, PM; Goujard, C; Lacombe, JM; Lahoulou, R; Potard, V; Valantin, MA | 1 |
| Cabot, JF; Denault, JS; Langlois, H; Marcotte, S; Sheehan, NL | 1 |
| Abraham, OC; Demosthenes, JP; Ghale, BC; Kannangai, R; Ramalingam, VV; Rupali, P; Varghese, GM | 1 |
| Boccuto, A; Dragoni, F; Giannini, A; Materazzi, A; Saladini, F; Vicenti, I; Zazzi, M | 1 |
| Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
| Borghetti, A; D'Avino, A; De Luca, A; Del Puente, F; Di Biagio, A; Irene Bonelli, S; Riccardi, N; Taramasso, L; Zazzi, M | 1 |
| Dunn, KJ; Kagan, RM; Kaufman, HW; Nettles, RE; Snell, GP | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| McNicholl, IR | 1 |
| Akuma, SH; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Schöller-Gyüre, M; Spittaels, K; Vyncke, V; Witek, J | 1 |
| DeMasi, R; Kakuda, TN; Mohammed, P; van Delft, Y | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Montrucchio, C; Trentini, L | 1 |
| Schrijvers, R | 1 |
| Asahchop, EL; Colby-Germinario, SP; Han, Y; McCallum, M; Oliveira, M; Quan, Y; Sarafianos, SG; Schader, SM; Wainberg, MA; Xu, HT | 1 |
| Adorni, F; Boeri, E; Bruzzone, B; Butini, L; Callegaro, A; Di Biagio, A; Galli, L; Galli, M; Gianotti, N; Meini, G; Monno, L; Pecorari, M; Polilli, E; Punzi, G; Rusconi, S | 1 |
| Bell, CS; Contreras, GA; Del Bianco, GP; Heresi, GP; Kleinosky, MT; Murphy, JR; Pérez, N | 1 |
| Anglaret, X; Chaix, ML; Danel, C; Eholie, SP; Gabillard, D; Kouakou, MG; Messou, E; Minga, A; Ouattara, E; Rouzioux, C; Toni, TD; Yapo, V | 1 |
| Bigoloni, A; Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Spagnuolo, V | 1 |
| Martín Carbonero, L; Moreno Celda, V; Ramírez-Olivencia, G; Valencia Ortega, ME | 1 |
| Blanco, JL; Gatell, JM; González-Cordon, A; Laguno, M; Lonca, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Monteiro, P; Perez, I | 1 |
| Colby-Germinario, SP; Han, Y; Oliveira, M; Quan, Y; Wainberg, MA; Xu, HT; Zanichelli, V | 1 |
| Conibear, T; Geretti, AM; Hill, A; Johnson, JA; Tambuyzer, L; Thys, K; Van Delft, Y; Vingerhoets, J | 1 |
| Almeida-González, CV; Calvo-Cidoncha, E; González-Bueno, J; Morillo-Verdugo, R | 1 |
| Bonjoch, A; Clotet, B; Echeverría, P; Moltó, J; Negredo, E; Ornelas, A; Paredes, R; Pérez-Álvarez, N; Puig, J; Sirera, G | 1 |
| Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Fortuna, S; Gagliardini, R; Navarra, P; Trecarichi, EM; Visconti, E | 1 |
| Cahn, P; Chokephaibulkit, K; Dincq, S; Fourie, J; Kakuda, TN; Karatzios, C; Nijs, S; Opsomer, M; Tambuyzer, L; Tomaka, FL; Tudor-Williams, G | 1 |
| Haddad, M; Napolitano, LA; Picchio, GR; Rimsky, LT; Van Eygen, V; Vingerhoets, J | 1 |
| Aga, E; Bartlett, J; Katzenstein, D; Kumarasamy, N; Norton, M; Ribaudo, H; Saravanan, S; Stevens, W; Wallis, CL | 1 |
| Battegay, M; Krasniqi, F; Kurz, M; Marzolini, C; Stoeckle, M | 1 |
| de la Torre-Lima, J; Delgado-Fernández, M; Garcia-Lázaro, M; Girón-González, JA; López-Cortés, LF; López-Ruz, MA; Lozano, F; Márquez-Solero, M; Martinez-Perez, MA; Mohamed-Balghata, MO; Romero-Palacios, A; Téllez-Pérez, F; Viciana, P | 1 |
| Bigoloni, A; Carbone, A; Castagna, A; Chiappetta, S; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Ripa, M; Spagnuolo, V; Tambussi, G | 1 |
| Aldieri, C; Bonora, S; Calcagno, A; Carbone, A; Castagna, A; D'Avolio, A; Di Perri, G; Ghisetti, V; Marinaro, L; Nozza, S; Trentalange, A | 1 |
| Crawford, KW | 1 |
| Aldamiz-Echevarria, T; Barros, C; Condés, E; de Cea, AM; González-Garcia, J; Moreno, A; Moreno, JS; Pérez-Elías, MJ; Quereda, C; Ramirez, ML; Santos, I; Torralba, M; Vargas, FX | 1 |
| Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Rodriguez, MA | 1 |
| Anderson, D; Brinson, C; Cho, M; Coate, B; Kakuda, TN; Ramgopal, M; Ruane, PJ; Ryan, R | 1 |
| Bateson, R; Calvez, V; Ceccherini-Silberstein, F; Clotet, B; Cozzi-Lepri, A; Flandre, P; Grarup, J; Günthard, HF; Hoogstoel, A; Incardona, F; Kaiser, R; Lavreys, L; Ledergerber, B; Lundgren, J; Marcelin, AG; Mercedes Santoro, M; Nelson, M; Nijs, S; Opsomer, M; Paredes, R; Perno, CF; Sonnerborg, A; Tambuyzer, L; Vingerhoets, J | 1 |
| Baccarani, U; Bassetti, M; Bonora, S; Dal Zoppo, S; Della Siega, P; Delle Foglie, P; Giglio, O; Londero, A; Nasta, P; Pea, F; Righi, E; Villa, G | 1 |
| Charpentier, C; Descamps, D; Fagard, C; Harrigan, PR; Katlama, C; Lee, GQ; Molina, JM; Rodriguez, C; Storto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Choi, JY; Kee, MK; Kim, SS; Kwon, OK; Oh, HR; Park, M; Rhee, JE | 1 |
| Calmy, A; Cavassini, M; Ciaffi, L; Delhumeau, C; Fehr, J; Genne, D; Hill, A; Hirschel, B; Montecucco, F; Schmid, P; Spycher Elbes, R; Stoeckle, M; Wandeler, G | 1 |
| Bañón, S; Casado, JL; Castro, A; Mena, A; Moreno, A; Moreno, S; Pedreira, J; Quereda, C | 1 |
| Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT | 1 |
| Eron, JJ; Floris-Moore, MA; Francis, O; Johnson, MA; Kashuba, AD; Kronk, C; Mollan, K; Patterson, KB; Wilkin, AM; Wohl, DA | 1 |
| De Meyer, S; Hoogstoel, A; Nijs, S; Opsomer, M; Tambuyzer, L; Thys, K; Tomaka, F; Vingerhoets, J | 1 |
| Belkhir, L; Capron, A; De Laveleye, M; Delongie, KA; Elens, L; Haufroid, V; Vandercam, B; Vincent, A; Yombi, J; Zech, F | 1 |
| Allavena, C; Cabie, A; Cheret, A; Cotte, L; Delobel, P; Duvivier, C; Hoen, B; Katlama, C; Lahoulou, R; Poizot-Martin, I; Pugliese, P; Raffi, F; Roger, PM | 1 |
| Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP | 1 |
| Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Fletcher, CV; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Wiznia, A; Yogev, R | 1 |
| Avihingsanon, A; Mekprasan, S; Ohata, PJ; Putcharoen, O; Ruxrungtham, K; Sirivichayakul, S; Teeranaipong, P | 1 |
| Baugh, B; Brown, K; Crauwels, HM; Hillewaert, V; Osiyemi, O; Ramgopal, M; Ryan, R; Zorrilla, C | 1 |
| Burger, DM; D'Avolio, A; Di Perri, G; Drenth, JP; Grintjes, K; Kanter, CT; Smolders, EJ; van Crevel, R | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Gonzalez, A; Graham, B; Hazra, R; Jean-Philippe, P; Larson, KB; Wiznia, A; Yogev, R | 1 |
| Megaly, M; Sharma, GK | 1 |
| Banda-Lara, MI; Chavez-García, M; Cruz-Herrera, JE; Domínguez-Hermosillo, JC; Gaytan-Martínez, JE; Huerta García, G; Manjarrez-Tellez, B; Mata-Marín, JA; Nuñez-Rodríguez, N; Sandoval-Ramírez, JL; Villagómez-Ruiz, A | 1 |
| Belkhir, L; Elens, L; Haufroid, V; Panin, N; Vandercam, B; Vincent, A; Yombi, JC; Zech, F | 1 |
| Gomathi, S; Kantor, R; Kausalya, B; Mothi, SN; Pachamuthu, B; Pradeep, A; Saravanan, S; Selvamuthu, P; Sivamalar, S; Smith, DM; Sunil, S | 1 |
| Borderi, M; Calza, L; Colangeli, V; Conti, M; Magistrelli, E; Mancini, R; Manfredi, R; Rossi, N; Viale, P | 1 |
| Audelin, AM; Jørgensen, LB; Lebech, AM; Petersen, AB | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Geretti, AM | 1 |
| Clotet, B; Llibre, JM; Moltó, J; Paredes, R; Puig, T; Ruiz, L; Santos, JR | 1 |
| Castagna, A; Lazzarin, A; Seminari, E | 1 |
| Calabresi, A; Carosi, G; Castelnuovo, F; Ceresoli, F; Costarelli, S; Gargiulo, F; Lapadula, G; Manca, N; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Clumeck, NN; Fätkenheuer, G; Gatell, J; Hay, P; Montaner, J; Peeters, MP; Schöller-Gyüre, M; Seminari, E; Simonts, M; Woodfall, B; Yeni, P | 1 |
| Arasteh, K; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, M; Pozniak, AL; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ; Workman, C | 1 |
| Conradie, F; De Smedt, G; Domingo, P; Kakuda, TN; Latiff, GH; Lupo, S; Pedro, RJ; Peeters, I; Peeters, M; Pumpradit, W; Ruxrungtham, K; Vingerhoets, JH; Woodfall, B | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Oddone, V; Sciandra, M; Siccardi, M; Simiele, M | 1 |
| Cerini, C; Fasan, S; Giacomet, V; Marchetti, G; Meroni, L; Pradella, A; Vanzulli, A; Viganò, A; Zuccotti, GV | 1 |
| Chantratita, W; Kiertiburanakul, S; Manosuthi, W; Piyavong, B; Sungkanuparph, S | 1 |
| Cartledge, JD; Lascar, M | 1 |
| Deeks, ED; Keating, GM | 1 |
| de Mendoza, C; González, Mdel M; Pattery, T; Poveda, E; Soriano, V; Villacian, J | 1 |
| Castro, J; Espinoza, L; Jayaweera, DT | 1 |
| Vallone, A; Vento, S | 1 |
| Berger, DS; Blick, G; Cohen, CJ; de Béthune, MP; Grossman, HA; Jayaweera, DT; Mack, R; Peeters, M; Shalit, P; Thompson, M; Voorspoels, E; Woodfall, B | 1 |
| Acosta, EP; King, JR; Long, MC | 1 |
| Couzigou, C; Escaut, L; Morand-Joubert, L; Roque-Afonso, AM; Seang, S; Vittecoq, D | 1 |
| Arazo Garcés, P; Omiste Sanvicente, T | 1 |
| García Deltoro, M | 1 |
| Aharchi, F; Beets, G; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Peeters, MP; Schöller-Gyüre, M; Vandermeulen, K; Woodfall, BJ | 1 |
| André, P; Brochier, C; Cotte, L; Gilibert, RP; Miailhes, P; Tardy, JC; Trabaud, MA; Trépo, C | 1 |
| Barreiro, P; Briz, V; de Mendoza, C; Garrido, C; Morello, J; Poveda, E; Soriano, V | 1 |
| Fulco, PP; McNicholl, IR | 1 |
| Sax, PE | 2 |
| Johnson, LB; Saravolatz, LD | 1 |
| Bregigeon, S; Drogoul, MP; Lacarelle, B; Martin, IP; Ménard, A; Mokthari, S; Solas, C; Tamalet, C | 1 |
| Bernardini, C; Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Secondo, G; Viscoli, C | 1 |
| Schiller, DS; Youssef-Bessler, M | 1 |
| Aboud, M; Back, D; Castelino, S; Kulasegaram, R | 1 |
| Arribas, JR | 2 |
| De Smedt, G; Haubrich, R; Katlama, C; Lalezari, J; Lazzarin, A; Madruga, JV; Molina, JM; Peeters, M; Picchio, G; Schechter, M; Vingerhoets, J; Woodfall, B | 1 |
| De Smedt, G; Hoetelmans, RM; Kakuda, TN; Raoof, A; Schöller-Gyüre, M | 1 |
| Böni, J; Bucher, HC; Bürgisser, P; Günthard, HF; Hasse, B; Klimkait, T; Ledergerber, B; Scherrer, AU; von Wyl, V; Yerly, S | 1 |
| Babrzadeh, F; Bachmann, MH; Blake, LA; Egholm, M; Fessel, WJ; Gharizadeh, B; Hanczaruk, B; Liu, T; Rhee, SY; Shafer, RW; Shahriar, R; Simen, BB; Varghese, V | 1 |
| Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Aumaître, H; Blanche, S; Chaix, ML; Firtion, G; Frange, P; Rabaud, C; Reliquet, V; Tamalet, C; Thuret, I; Tricoire, J | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Loutfy, M; Marks, S; Ribera, E; Ryan, R; van Delft, Y; Vanaken, H | 1 |
| Alloui, C; Barin, F; Bettinger, D; Bouvier-Alias, M; Calvez, V; Charpentier, C; Cottalorda, J; Delaugerre, C; Descamps, D; Dos Santos, G; Flandre, P; Henquell, C; Izopet, J; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Rogez, S; Ruffault, A; Saoudin, H; Signori-Schmuck, A; Tamalet, C; Trabaud, MA; Vallet, S | 1 |
| Sanne, I; Stevens, WS; Venter, F; Wallis, CL | 1 |
| Moore, K; Radzio, J; Sluis-Cremer, N; Sonza, S; Tachedjian, G | 1 |
| Antinori, A; Ceccherini-Silberstein, F; Cozzi-Lepri, A; Monforte, Ad; Mussini, C; Palamara, G; Perno, CF; Santoro, MM; Spagnuolo, V; Zaccarelli, M | 1 |
| Azijn, H; de Béthune, MP; De Smedt, G; Hoogstoel, A; Nijs, S; Peeters, M; Picchio, G; Tambuyzer, L; Vingerhoets, J; Woodfall, B | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H | 1 |
| Caldwell, DJ; Elsayed, RK | 1 |
| Domingo, P | 2 |
| Estévez, MA; García, FG; Suay, VG | 1 |
| Corbera, EF; Palter, DP; Tiraboschi, JM | 1 |
| Garcés, PA; Tena, EV | 1 |
| Portilla, J | 1 |
| Pérez, VE; Sánchez-Parra, C; Serrano Villar, S | 1 |
| Clotet, B; Llibre, JM; Santos, JR | 1 |
| Santos Gil, Ide L | 1 |
| Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M | 1 |
| Bigoloni, A; Canducci, F; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Salpietro, S; Soria, A; Tambussi, G; Torre, LD; Visco, F | 1 |
| Azijn, H; De Meyer, S; Hill, A; Peeters, M; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Adewole, I; Akanmu, S; Chaplin, B; Gashau, W; Idoko, J; Kanki, P; Meloni, S; Murphy, R; Penugonda, S; Taiwo, B | 1 |
| Chantratita, W; Kiertiburanakul, S; Sukasem, C; Sungkanuparph, S; Wiboonchutikul, S | 1 |
| de Souza, DF; Diaz, RS; Inocencio, LA; Janini, LM; Munerato, P; Oliveros, MP; Pereira, AA; Sucupira, MC | 1 |
| Adorni, F; Antinori, A; Boeri, E; Bruzzone, B; Callegaro, A; Di Biagio, A; Di Vincenzo, P; Francisci, D; Maggiolo, F; Monno, L; Perno, CF; Punzi, G; Rusconi, S; Vitiello, P; Zazzi, M | 1 |
| Briz, V; de José, MI; González-Tomé, MI; León Leal, JA; Muñoz-Fernández, MA; Navarro, ML; Palladino, C; Ramos, JT | 1 |
| Ananworanich, J; Chokephaibulkit, K; Hansudewechakul, R; Hongsiriwon, S; Jourdain, G; Kosalaraksa, P; Petdachai, W; Puthanakit, T; Siangphoe, U; Sirisanthana, V; Suntarattiwong, P; Suwanlerk, T | 1 |
| Hull, MW; Montaner, JS | 1 |
| Bellagamba, R; D'offizi, G; Fezza, R; Narciso, P; Nicastri, E; Pucillo, LP; Tempestilli, M; Tommasi, C | 1 |
| Holmes, SP; Reuman, EC; Rhee, SY; Shafer, RW | 1 |
| Azijn, H; de Béthune, MP; De Meyer, S; De Smedt, G; Dierynck, I; Nijs, S; Picchio, G; Rimsky, L; Tambuyzer, L; Vingerhoets, J | 1 |
| Butler, DM; Chantratita, W; Manosuthi, W; Richman, DD; Smith, DM; Sukasem, C | 1 |
| Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 2 |
| Decha, P; Hannongbua, S; Intharathep, P; Parasuk, V; Sompornpisut, P; Udommaneethanakit, T; Wolschann, P | 1 |
| Fujii, T; Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Miyazaki, N; Nakamura, H; Odawara, T | 1 |
| Antoniou, T; Bitnun, A; Brophy, J; Jaworsky, D; Loutfy, MR; Samson, L; Thompson, C; Yudin, MH | 1 |
| Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; He, QQ; Liang, YH; Pannecouque, C; Zeng, ZS | 1 |
| De Smedt, G; Di Perri, G; Grinsztejn, B; Peeters, M; Towner, W; Woodfall, B | 1 |
| Hamaguchi, M; Hirano, A; Kinoshita, E; Nomura, T; Shibata, M; Sugiura, W; Takahashi, M; Yokomaku, Y | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Coluccia, A; La Regina, G; Silvestri, R | 1 |
| Clotet, B; Clumeck, N; Katlama, C; Nijs, S; Witek, J | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Cassetti, I; Domingo, P; Kakuda, TN; Nijs, S; Towner, WJ; Vingerhoets, J; Woodfall, B | 1 |
| Hoetelmans, RM; Kakuda, TN; Schöller-Gyüre, M | 1 |
| Arumugam, K; D'souza, G; De Costa, A; Gupta, S; Kuttiatt, VS; Neogi, U; Prarthana, BS; Shet, A | 1 |
| Azijn, H; Daems, B; de Béthune, MP; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| De Smedt, G; Kakuda, TN; Mills, A; Peeters, M; Vingerhoets, J; Woodfall, B; Yeni, P | 1 |
| Anderson, D; Fullerton, DS; Martin, SC; Mrus, JM; Watson, MJ; Witek, J | 1 |
| Barrail-Tran, A; Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Goldwirt, L; Katlama, C; Molina, JM; Piketty, C; Taburet, AM; Yazdanpanah, Y | 1 |
| Bailey, JR; Gallant, JE; Pham, PA; Reiss, KA | 1 |
| Clotet, B; Grinsztejn, B; Haubrich, R; Katlama, C; Mills, A; Molina, JM; Nijs, S; Towner, W; Trottier, B; Vingerhoets, J; Witek, J; Woodfall, B | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Delhumeau, C; Elzi, L; Fayet-Mello, A; Genné, D; Hirschel, B; Mercier, IK; Nguyen, A; Rauch, A | 1 |
| Back, D; Dickinson, L; Khoo, S | 1 |
| Alas, B; Perniciaro, A; Ruane, P; Ryan, R; Witek, J | 1 |
| Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A | 1 |
| Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Oliveira, M; Toni, Td; Tremblay, CL; Wainberg, MA | 1 |
| Banhegyi, D; Gazzard, B; Hill, A; Marks, S; Nelson, M; Podzamczer, D; Stark, T; Stellbrink, HJ; van Delft, Y; Vingerhoets, J | 1 |
| Falcon, R; Jennings, S; Kashuba, A; Mrus, J; Patterson, K | 1 |
| Cahn, P; Clumeck, N; Mills, A; Molina, JM; Nijs, S; Vingerhoets, J; Witek, J | 1 |
| Ghosn, J | 1 |
| Giguère, P; Kravcik, S; la Porte, CJ; Toy, J | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Lazzarin, A; Nicola, G; Nozza, S; Pogliaghi, M; Salpietro, S; Tambussi, G | 1 |
| Tian, XT; Xie, L | 1 |
| Feys, C; Izurieta, P; Kakuda, TN; Witek, J | 1 |
| Briz, V; de José, M; González-Tomé, M; Jiménez de Ory, S; León, J; Muñoz-Fernández, M; Navarro, M; Núñez-Cuadros, E; Palladino, C; Ramos, J | 1 |
| Cattaneo, D; Gervasoni, C | 1 |
| Ekstrand, ML; Neogi, U; Shamsundar, R; Shet, A | 1 |
| Bellagamba, R; D'Avolio, A; Gallo, AL; Ivanovic, J; Narciso, P; Nicastri, E; Pucillo, LP; Tempestilli, M; Tommasi, C | 1 |
| Daems, B; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Lazzarin, A; Nozza, S | 1 |
| Bambara, RA; Demeter, LM; Dykes, C; Li, D; Liang, H; Lowe, NR; Smith, HM; Wang, J; Wu, H; Zhang, G | 1 |
| Claassen, M; Preiser, W; van der Merwe, L; van Zyl, GU; Zeier, M | 1 |
| Hu, Z; Kuritzkes, DR | 1 |
| Aleixo, AW; Arruda, MB; de M Brindeiro, R; Greco, DB; Martins, AN; Pires, AF; Tanuri, A | 1 |
| Castagna, A; Duvivier, C; Gazzard, B; Hill, A; Marks, S; van Delft, Y; Zagler, C | 1 |
| Bacheler, L; Lecocq, P; Van Craenenbroeck, E; Van der Borght, K; Van Houtte, M; Van Kerckhove, B; van Vlijmen, H; Verbeke, G | 1 |
| Do, VT; Fulco, PP; Higginson, RT | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
| Giaquinto, C; Penazzato, M | 1 |
| Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A | 1 |
| Castillo-Ferrando, JR; Gutiérrez-Valencia, A; López-Cortés, LF; Martin-Peña, R; Ruiz-Valderas, R; Torres-Cornejo, A | 1 |
| Durant, J; Duvivier, C; Fätkenheuer, G; Hill, A; Marks, S; Rey, D; Rieger, A; Schmidt, W; van Delft, Y | 1 |
| Bettinger, D; Bouvier-Alias, M; Calvez, V; Cottalorda, J; Delaugerre, C; Descamps, D; Flandre, P; Henquell, C; Izopet, J; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Rogez, S; Ruffault, A; Signori-Schmuck, A; Tamalet, C; Trabaud, MA; Vallet, S | 1 |
| Gough, K; Kovacs, C; Naccarato, M; Yoong, D | 1 |
| Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P | 1 |
| Duque, V; Meliço-Silvestre, A; Morais, C; Mota, V; Pereira, B; Pereira-Vaz, J; Saraiva-da-Cunha, J | 1 |
| Niubo, J; Perez-Pujol, S; Podzamczer, D; Tiraboschi, JM; Vila, A | 1 |
| Acosta, EP; Fletcher, CV; Moore, R; Sandkovsky, U; Swindells, S | 1 |
| Croxtall, JD | 1 |
| Anquetil, D; Deshpande, A; Fleury, HJ; Le Bihan, L; Pinson, PR; Zongo, D | 1 |
| Blanc, C; Clavel, C; Courbon, E; Crenn-Hebert, C; Ichou, H; Katlama, C; Mandelbrot, L; Marcelin, AG; Peytavin, G; Schneider, L; Soulié, C; Tubiana, R | 1 |
| Balamane, M; Fessel, WJ; Katzenstein, DA; Melikian, GL; Shafer, RW; Varghese, V | 1 |
| Fang, J; Jadhav, PR | 1 |
| Dhiver, C; Durant, J; Gagnieu, MC; Garraffo, R; Katlama, C; Lê, MP; Muret, P; Peytavin, G; Poizot-Martin, I; Solas, C; Yeni, P | 1 |
| Anderson, D; Hoogstoel, A; Nijs, S; Picchio, G; Tambuyzer, L; Vingerhoets, J | 1 |
| Cedeño, S; Clotet, B; Miranda, C; Moltó, J; Negredo, E; Valle, M | 1 |
| Lyseng-Williamson, KA | 1 |
| Agher, R; Calin, R; Katlama, C; Paris, L; Peytavin, G; Schneider, L; Simon, A; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Barrera-Castillo, G; Ferrer, E; Maso-Serra, M; Niubo, J; Podzamczer, D; Rozas, N; Tiraboschi, JM | 1 |
| Delviks-Frankenberry, KA; Kearney, MF; Lengruber, RB; Maldarelli, F; Pathak, VK; Santos, AF; Silveira, JM; Soares, MA | 1 |
| Arab-Alameddine, M; Bernasconi, E; Buclin, T; Calmy, A; Cavassini, M; Csajka, C; Decosterd, LA; di Iulio, J; Fayet-Mello, A; Furrer, H; Guidi, M; Günthard, HF; Lubomirov, R; Martinez, R; Marzolini, C; Rotger, M; Telenti, A | 1 |
| Liedtke, MD; Rathbun, RC; Vanguri, A | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Dilanchian, P; Jayaweera, D | 1 |
| Asahchop, EL; Brenner, BG; Ibanescu, IR; Moisi, D; Oliveira, M; Tremblay, C; Wainberg, MA; Xu, H | 1 |
| Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G | 1 |
| Best, BM; Capparelli, E; Clifford, D; Collier, AC; Croteau, D; Ellis, RJ; Gelman, B; Grant, I; Letendre, S; Marra, C; McArthur, J; McCutchan, JA; Morgello, S; Nguyen, A; Rossi, S; Simpson, D | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Taburet, AM; Visseaux, B; Yazdanpanah, Y | 1 |
| Agneskog, E; Källander, CF; Nowak, P; Sönnerborg, A | 1 |
| Aharchi, F; Hoetelmans, RM; Kakuda, TN; Nijs, S; Smedt, GD; Van Solingen-Ristea, R; Vyncke, V; Witek, J | 1 |
| Feinberg, J | 1 |
| Susman, E | 1 |
| Baede-Van Dijk, P; de Dier, K; Doubovskaya, E; Gruzdev, B; Parys, W; Peeters, M; Rakhmanova, A; Rinehart, A; van 't Klooster, G; Yakovlev, A | 1 |
| Danner, SA; Gruzdev, B; Jurriaans, S; Lange, JM; Peeters, M; Prins, JM; Rakhmanova, A; Sankatsing, SU; van't Klooster, G; Weverling, GJ | 1 |
| Arasteh, K; De Dier, K; Gazzard, BG; Peeters, M; Pozniak, AL; Rosenbaum, W; Staszewski, S; Stebbing, J; vant' Klooster, GA; Woodfall, B; Yeni, GP | 1 |
| Arendt, G; Haslinger, BA | 1 |
| James, JS | 1 |
| Pauwels, R | 1 |
| Fransen, K; Garcia, S; Janssen, CG; Janssen, PA; Kestens, L; Lewi, PJ; Njai, HF; Vanham, G | 1 |
| Boone, LR | 1 |
| Hicks, CB | 1 |
| Boffito, M; Mallon, PW; Winston, A | 1 |
| Bernard, AJ; Boffito, M; Churchill, D; Edwards, S; Fisher, N; Gazzard, B; Geretti, AM; Johnson, M; Leen, C; Peters, B; Pozniak, A; Ross, J; Walsh, J; Wilkins, E; Youle, M | 1 |
| Temesgen, Z | 1 |
| Berger, DS; Blick, G; Cimoch, PJ; Cohen, CJ; Greenberg, RN; Hicks, CB; Hoetelmans, RM; Iveson, KJ; Jayaweera, DS; Mills, AM; Nadler, JP; Peeters, MP; Ruane, PJ; Schrader, SR; Shalit, P; Smith, SM; Steinhart, CR; Thompson, M; Vingerhoets, JH; Voorspoels, E; Ward, D; Woodfall, B | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, P | 1 |
| Deeks, SG; Hatano, H | 1 |
| Colquitt, AR; Pham, PA | 1 |
| Boffito, M; Fletcher, C; Gazzard, B; Hoetelmans, R; Jackson, A; Miralles, D; Moyle, G; Nelson, M; Pozniak, A; Tolowinska, I; Winston, A | 1 |
| Hirschel, B; Perneger, T | 1 |
| Cahn, P; de Smedt, G; Grinsztejn, B; Haubrich, R; Lalezari, J; Leopold, L; Madruga, JV; Mills, A; Peeters, M; Pialoux, G; Trefiglio, R; Vingerhoets, J; Wilkin, T; Woodfall, B | 1 |
| Baeten, B; Beets, G; Campbell, T; Clotet, B; de Smedt, G; Johnson, M; Katlama, C; Lazzarin, A; Moll, A; Peeters, M; Sinha, R; Towner, W; Trottier, B; Vingerhoets, J; Woodfall, B | 1 |
| Kuritzkes, DR | 1 |
| Cobo, J; Corral, A; de Mendoza, C; Garrido, C; González-Lahoz, J; Poveda, E; Soriano, V | 1 |
| Knoll, BM; Temesgen, Z; Vento, S | 1 |
| Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Rusconi, S; Viganò, O; Viscoli, C | 1 |
| Taéron, C | 1 |
| Grover, D; Nelson, M; Scott, C | 1 |
| Stephenson, J | 1 |
47 review(s) available for etravirine and HIV Coinfection
| Article | Year |
|---|---|
Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Biological Availability; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Multiple Organ Failure; Nitriles; Pharmacogenetics; Pregnancy; Pyrimidines; Reverse Transcriptase Inhibitors | 2020 |
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Cyclopropanes; Dideoxynucleosides; Endothelial Cells; HIV Infections; Humans; Neurons; Nevirapine; Nitriles; Oligodendroglia; Pyrimidines | 2020 |
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2017 |
Does once-daily etravirine have a role in the management of HIV-1 infection?
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Half-Life; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Viral Load | 2013 |
Etravirine for the treatment of HIV/AIDS.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2013 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
Shifting paradigms: the resistance profile of etravirine.
Topics: Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2008 |
Etravirine for the treatment of HIV infection.
Topics: Anti-HIV Agents; HIV Infections; Humans; Molecular Structure; Nitriles; Pyridazines; Pyrimidines | 2008 |
New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Topics: Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Treatment Outcome | 2008 |
Etravirine.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2008 |
Pharmacologic aspects of new antiretroviral drugs.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Nitriles; Organophosphonates; Oxazines; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides | 2009 |
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia | 2008 |
[Resistance to darunavir].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Lopinavir; Male; Multicenter Studies as Topic; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Phenotype; Point Mutation; Pyridazines; Pyrimidines; Pyrimidinones; Randomized Controlled Trials as Topic; Sulfonamides | 2008 |
Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2009 |
Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Clinical pharmacokinetics and pharmacodynamics of etravirine.
Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Ritonavir; Sulfonamides | 2009 |
Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for managing human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
[Chemical characteristics, mechanism of action and antiviral activity of etravirine].
Topics: Allosteric Site; Anti-HIV Agents; Binding Sites; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Structure; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2009 |
[Etravirine in highly treatment-experienced patients].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genes, pol; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2009 |
[Etravirine in first-line therapy].
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Interactions; Drug Resistance, Multiple, Viral; Genes, pol; Hepatitis, Viral, Human; Heroin Dependence; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mental Disorders; Methadone; Multicenter Studies as Topic; Nitriles; Patient Compliance; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous | 2009 |
[Safety and tolerability of etravirine].
Topics: Animals; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Drug Eruptions; Drug Evaluation, Preclinical; Dyslipidemias; Female; Fetus; Gastrointestinal Diseases; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Mental Disorders; Multicenter Studies as Topic; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Quality of Life; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides | 2009 |
[Etravirine drug interactions].
Topics: Analgesics; Anesthetics; Anti-HIV Agents; Anti-Infective Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Biotransformation; Contraceptives, Oral, Hormonal; Contraindications; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Microsomes, Liver; Nitriles; Piperazines; Purines; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones | 2009 |
[Etravirine: genetic barrier and resistance development].
Topics: Anti-HIV Agents; Databases, Genetic; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Genes, pol; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Mutation, Missense; Nitriles; Point Mutation; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Selection, Genetic | 2009 |
[Etravirine in special populations].
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Child; Comorbidity; Drug Interactions; Female; Fetus; Hepatitis B; Hepatitis C; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mental Disorders; Multicenter Studies as Topic; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Psychotropic Drugs; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Renal Insufficiency; Reverse Transcriptase Inhibitors | 2009 |
[Role of etravirine in combination antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Interactions; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mental Disorders; Multicenter Studies as Topic; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2009 |
A review of the safety and tolerability profile of the next-generation NNRTI etravirine.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Exanthema; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Time Factors; Treatment Outcome; Withholding Treatment | 2010 |
Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Binding Sites; Cell Line; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Models, Molecular; Molecular Conformation; Nitriles; Phosphinic Acids; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Quinoxalines; Reverse Transcriptase Inhibitors; Rilpivirine | 2010 |
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2010 |
Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.
Topics: Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2010 |
Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2010 |
Pharmacoeconomics of etravirine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Economics, Pharmaceutical; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Quality of Life; Quality-Adjusted Life Years; RNA, Viral | 2010 |
Pharmacokinetic evaluation of etravirine.
Topics: Animals; Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
[Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2010 |
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2011 |
Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2012 |
New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; HIV; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
TMC-125 Tibotec.
Topics: Animals; Clinical Trials as Topic; Drugs, Investigational; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Technology, Pharmaceutical | 2004 |
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Models, Molecular; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfur Compounds | 2004 |
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Animals; Anti-HIV Agents; Azepines; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2006 |
The clinical pharmacology of antiretrovirals in development.
Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2006 |
Etravirine: R165335, TMC 125, TMC-125, TMC125.
Topics: Administration, Oral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Disease Progression; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; Humans; Integrase Inhibitors; Male; Nitriles; Patient Compliance; Pyridazines; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Risk Assessment; Sulfonamides; United Kingdom | 2006 |
Etravirine.
Topics: Anti-HIV Agents; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2008 |
59 trial(s) available for etravirine and HIV Coinfection
| Article | Year |
|---|---|
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2020 |
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Prospective Studies; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load | 2021 |
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Young Adult | 2018 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Gels; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Young Adult | 2013 |
Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Cross-Over Studies; Darunavir; Drug Interactions; Ethanolamines; Fluorenes; Healthy Volunteers; HIV; HIV Infections; Humans; Lumefantrine; Malaria; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2013 |
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance; Europe; Female; Genotyping Techniques; HIV Infections; HIV-1; Humans; Israel; Male; Microbial Sensitivity Tests; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Russia; Treatment Outcome; Young Adult | 2014 |
Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
Topics: Adult; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Middle Aged; Nitriles; Patient Satisfaction; Pyridazines; Pyrimidines; Treatment Outcome | 2014 |
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Topics: Adolescent; Area Under Curve; Child; Drug Eruptions; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Medication Adherence; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2014 |
Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.
Topics: Drug Therapy, Combination; Endpoint Determination; Gene Expression Regulation, Viral; HIV Infections; Humans; Kaplan-Meier Estimate; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Spain; Treatment Outcome | 2014 |
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Cell Count; Cyclohexanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2014 |
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retreatment; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult | 2015 |
The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Topics: Adult; Aged; Anti-HIV Agents; Body Fat Distribution; Bone Density; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2015 |
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data.
Topics: CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Meta-Analysis as Topic; Middle Aged; Nitriles; Odds Ratio; Pyridazines; Pyrimidines; Ritonavir; Spain; Sulfonamides; Switzerland; United Kingdom; Viral Load | 2015 |
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Biomarkers; Cardiovascular Diseases; Cyclopropanes; Drug Substitution; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Young Adult | 2015 |
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy | 2015 |
Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Treatment Outcome; Viral Load; Young Adult | 2016 |
Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Topics: Adolescent; Anti-HIV Agents; Child; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Treatment Failure | 2016 |
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Treatment Outcome | 2016 |
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
Topics: Adolescent; Darunavir; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult | 2017 |
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pyridazines; Pyrimidines; Young Adult | 2016 |
Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines | 2008 |
Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Epidemiologic Methods; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Young Adult | 2008 |
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Single-Blind Method; Treatment Outcome; Viral Load | 2009 |
Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Belgium; Cross-Over Studies; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Netherlands; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Tenofovir; Young Adult | 2009 |
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Double-Blind Method; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Young Adult | 2009 |
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pilot Projects; Pyridazines; Pyrimidines; RNA, Viral; Treatment Outcome | 2009 |
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2010 |
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Nitriles; Placebos; Pyridazines; Pyrimidines | 2010 |
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
A randomized crossover study to compare efavirenz and etravirine treatment.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Anxiety Disorders; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Treatment Outcome | 2011 |
A 48-week pilot study switching suppressed patients to darunavir/ritonavir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Protease; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pilot Projects; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Feasibility Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viral Load | 2011 |
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Topics: Adult; Darunavir; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides | 2011 |
Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Nitriles; Phenotype; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2010 |
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2011 |
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2011 |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Blood Cells; Chromatography, Liquid; Female; HIV Infections; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Plasma; Pyridazines; Pyrimidines | 2012 |
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV; HIV Infections; Humans; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyridazines; Pyrimidines; Viral Load; Young Adult | 2012 |
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Topics: Adenine; Anti-HIV Agents; Cyclohexanes; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Maraviroc; Models, Biological; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; RNA, Viral; Tenofovir; Triazoles | 2012 |
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Echinacea; Female; Herb-Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Nitriles; Plant Extracts; Pyridazines; Pyrimidines | 2012 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Topics: Anti-HIV Agents; Darunavir; DNA, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides | 2013 |
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Female; Fluconazole; Genotype; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles; Voriconazole; Young Adult | 2013 |
A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
Topics: Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2003 |
TMC125: important one-year trial now recruiting in U.S.
Topics: HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; United States | 2004 |
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
Topics: Adult; CD4 Lymphocyte Count; Dreams; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mood Disorders; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Severity of Illness Index | 2007 |
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Double-Blind Method; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Viral Load | 2007 |
NDA submitted for TMC125.
Topics: Adult; Anti-HIV Agents; Drug Approval; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; United States; United States Food and Drug Administration | 2007 |
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance?
Topics: Anti-HIV Agents; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Failure | 2008 |
197 other study(ies) available for etravirine and HIV Coinfection
| Article | Year |
|---|---|
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Computer-Aided Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; Models, Molecular; Molecular Structure; Monte Carlo Method; Mutation; Reverse Transcriptase Inhibitors | 2006 |
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Amines; Drug Resistance, Multiple, Viral; Heterocyclic Compounds; HIV Infections; HIV Reverse Transcriptase; Hydrophobic and Hydrophilic Interactions; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiazoles | 2006 |
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Pyridines; Structure-Activity Relationship | 2009 |
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine | 2010 |
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Phylogeny; Pyridazines; Pyrimidines | 2010 |
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Models, Molecular; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Recombination, Genetic; Virus Replication | 2010 |
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Aniline Compounds; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydrogen Bonding; Magnetic Resonance Spectroscopy; Models, Molecular; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2010 |
Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Mutation; Piperidines; Pyrimidines; Structure-Activity Relationship | 2010 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
Topics: Aniline Compounds; Anti-HIV Agents; Cell Line; Drug Design; Ether; HIV Infections; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors | 2015 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2016 |
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Keto Acids; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors | 2017 |
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes | 2017 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2019 |
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Apoptosis; Drug Design; Female; HIV Infections; HIV-1; Humans; Ligands; Male; Mice; Microsomes, Liver; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution; Tumor Cells, Cultured; Virus Replication | 2019 |
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2022 |
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load | 2023 |
Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands.
Topics: Anti-HIV Agents; COVID-19; HIV Infections; Humans; Integrases; Molecular Docking Simulation; Netherlands; SARS-CoV-2; Tenofovir | 2023 |
Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Topics: Anti-HIV Agents; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium | 2020 |
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Nitriles; Pyrimidines; Raltegravir Potassium | 2020 |
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' res
Topics: Anti-HIV Agents; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium | 2020 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Treatment Outcome | 2021 |
Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; France; Gene Expression Regulation, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Propensity Score; Pyridazines; Pyrimidines; Raltegravir Potassium; RNA, Viral; Viral Load | 2017 |
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia | 2018 |
High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches.
Topics: Activation, Metabolic; Adult; Aged; Chromatography, Liquid; Female; Glutathione; HIV Infections; Humans; Liver; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2018 |
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult | 2018 |
Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Hospitalization; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Risk; Ritonavir; RNA, Viral; Viral Load; Young Adult | 2018 |
Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
Topics: Anti-Retroviral Agents; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Quinolones | 2019 |
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sweden | 2019 |
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro.
Topics: DNA Mutational Analysis; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutant Proteins; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Selection, Genetic; Serial Passage; Virus Cultivation | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Is it time to re-think the use of etravirine in patients with available genotypic resistance test?
Topics: HIV; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Sweden | 2019 |
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Topics: Anti-HIV Agents; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2019 |
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Topics: Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Quality of Life; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2019 |
Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Female; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; RNA, Viral; Sulfonamides; Treatment Failure; Triazoles; Viral Load | 2013 |
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
Topics: Anti-HIV Agents; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2013 |
Prevalence of etravirine (ETR)-RAMs at NNRTI failure and predictors of resistance to ETR in a large Italian resistance database (ARCA).
Topics: Adult; Child; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Italy; Male; Multivariate Analysis; Nitriles; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure | 2013 |
Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Male; Mutation, Missense; Nitriles; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Risk Factors | 2013 |
Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Monitoring; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Time Factors; Viral Load | 2013 |
Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine.
Topics: Adult; Anti-HIV Agents; Glucose Tolerance Test; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Protease Inhibitors; Pyridazines; Pyrimidines | 2013 |
[Etravirine in clinical practice: Experience in 151 non-naïve patients].
Topics: Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2013 |
Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
Topics: Anti-HIV Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2014 |
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Topics: Amino Acid Motifs; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2014 |
Influence of adding etravirine on complexity index and patients' perceived complexity.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Treatment Outcome | 2014 |
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Interactions; Female; HIV Infections; Humans; Nitriles; Plasma; Pyridazines; Pyrimidines; Rifampin; Tuberculosis | 2014 |
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nitriles; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; United States | 2014 |
Drug susceptibility and resistance mutations after first-line failure in resource limited settings.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; India; Lopinavir; Malawi; Male; Middle Aged; Mutation Rate; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Tanzania; Thailand; Treatment Failure; Young Adult | 2014 |
Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Fever; HIV Infections; HIV-1; Hodgkin Disease; Humans; Male; Middle Aged; Nitriles; Prednisone; Procarbazine; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome; Vincristine; Viral Load | 2015 |
Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients.
Topics: Adult; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Nitriles; Plasma; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load | 2014 |
Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir.
Topics: Adult; Antiviral Agents; Cohort Studies; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Nitriles; Oligopeptides; Pyridazines; Pyrimidines; Retrospective Studies; Spain; Treatment Outcome | 2014 |
Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2015 |
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.
Topics: Anti-Retroviral Agents; Coinfection; Cyclohexanes; Darunavir; Drug Monitoring; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Liver Transplantation; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Triazoles | 2015 |
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Longitudinal Studies; Mutation; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load | 2015 |
Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation; Nitriles; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Precursors; Pyridazines; Pyrimidines; Recombination, Genetic; Republic of Korea | 2015 |
Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Topics: Adult; Aged; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Coinfection; Female; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Treatment Outcome | 2016 |
Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a pote
Topics: Biomarkers; Chromatography, High Pressure Liquid; Cohort Studies; Darunavir; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Limit of Detection; Male; Middle Aged; Nitriles; Prognosis; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2016 |
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2016 |
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Thailand; Viral Load; Young Adult | 2016 |
Sixty milligram daclatasvir is the right dose for hepatitis C virus treatment in combination with etravirine and darunavir/ritonavir.
Topics: Anti-HIV Agents; Antiviral Agents; Area Under Curve; Carbamates; Coinfection; Darunavir; Diuretics; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidines; Renal Insufficiency; Ritonavir; Treatment Outcome; Valine | 2016 |
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Female; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2016 |
Etravirine as a culprit of recurrent drug-eluting in-stent restenosis in an HIV patient.
Topics: Clopidogrel; Coronary Restenosis; Drug Interactions; Drug-Eluting Stents; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ticlopidine | 2016 |
Effectiveness of etravirine-based therapy for treatment-experienced HIV-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; RNA, Viral; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult | 2016 |
Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
Topics: Adult; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Polymorphism, Genetic; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2016 |
Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Male; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Rilpivirine; Sequence Analysis, DNA; Treatment Failure | 2017 |
Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; Humans; Maintenance Chemotherapy; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome | 2017 |
Etravirine(Intelence) for HIV infection.
Topics: Anti-HIV Agents; Drug Costs; Drug Interactions; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Nitriles; Patient Compliance; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Virus Replication | 2008 |
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines | 2008 |
FDA notifications. FDA grants accelerated approval for etravirine.
Topics: Drug Approval; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Italy; Logistic Models; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; Prevalence; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Treatment Failure | 2008 |
An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sensitivity and Specificity | 2008 |
Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues.
Topics: Anti-HIV Agents; Disease Susceptibility; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Phenotype; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Failure | 2008 |
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2008 |
Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome | 2008 |
No hepatotoxicity found for etravirine.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2008 |
Efficacy of etravirine for treatment of acute HIV meningoencephalitis.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Female; Hepatitis C; HIV; HIV Infections; Humans; Meningoencephalitis; Nitriles; Pyridazines; Pyrimidines; Treatment Outcome | 2009 |
Two studies look at Intelence.
Topics: CD4-Positive T-Lymphocytes; HIV Infections; Humans; Nitriles; Placebos; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Viral Load | 2008 |
Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
Topics: Algorithms; Anti-HIV Agents; Databases, Genetic; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Predictive Value of Tests; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Raltegravir and etravirine are active against HIV type 1 group O.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Middle Aged; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Viral Load | 2009 |
Report from the 15th Retrovirus Conference. Etravirine resistance: baseline prevalence and proposed criteria for "vircotype".
Topics: Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2008 |
Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2009 |
Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
Topics: Adolescent; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Male; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Etravirine plasma levels in a patient with decompensated liver disease.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Liver Cirrhosis; Middle Aged; Nitriles; Pyridazines; Pyrimidines | 2009 |
Etravirine: new drug. Multidrug-resistant HIV: another option.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Approval; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Viral; Europe; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2009 |
Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
Topics: Algorithms; Anti-HIV Agents; Cohort Studies; Drug Resistance, Multiple, Viral; Gene Frequency; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nitriles; Polymorphism, Genetic; Predictive Value of Tests; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Switzerland; Treatment Failure; Viral Load | 2009 |
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genetic Variation; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines | 2009 |
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nitriles; Phylogeny; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Treatment Outcome | 2010 |
Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa?
Topics: Africa, Southern; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Failure | 2009 |
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
Topics: Adenine; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mutation; Nitriles; Pyridazines; Pyrimidines; Young Adult | 2010 |
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Topics: Anti-HIV Agents; Clinical Trials, Phase III as Topic; Disease Susceptibility; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Phenotype; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Viral Load | 2010 |
[Introduction. Etravirine: a new standard of potency and safety among non-nucleoside analogues].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Reverse Transcriptase; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2009 |
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Salvage Therapy; Triazoles; Viral Load | 2010 |
Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
Topics: Antiretroviral Therapy, Highly Active; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Treatment Failure; Viral Load; Viral Proteins | 2010 |
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Thailand; Treatment Outcome | 2010 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).
Topics: Adult; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Male; Multivariate Analysis; Mutation; Nitriles; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Failure | 2010 |
Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
Topics: Adolescent; Child; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2010 |
HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Predictive Value of Tests; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Thailand; Treatment Failure; Viral Load | 2010 |
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in t
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Viral Load | 2010 |
A rare case of severe myopathy associated with etravirine use.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Middle Aged; Muscular Diseases; Nitriles; Pyridazines; Pyrimidines | 2010 |
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
Topics: Anti-HIV Agents; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Nitriles; Phenotype; Pyridazines; Pyrimidines; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Treatment Failure | 2010 |
FDA notifications. Etravirine label updated by FDA.
Topics: Drug Labeling; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2010 |
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
Topics: Anti-HIV Agents; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Salvage Therapy; Sulfonamides | 2010 |
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Biological; Molecular Dynamics Simulation; Mutation; Nevirapine; Nitriles; Protein Binding; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Thermodynamics; Uracil; Water | 2011 |
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2011 |
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nitriles; Protein Binding; Pyridazines; Pyrimidines; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2010 |
High performance liquid chromatography using UV detection for the simultaneous quantification of the new non-nucleoside reverse transcriptase inhibitor etravirine (TMC-125), and 4 protease inhibitors in human plasma.
Topics: Calibration; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Spectrophotometry, Ultraviolet | 2010 |
Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Male; Middle Aged; Molecular Sequence Data; Nitriles; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; Polymorphism, Genetic; Pyridazines; Pyrimidines; RNA, Viral; Sequence Analysis, RNA; Thymidine | 2010 |
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Darunavir; Drug Resistance, Viral; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation, Missense; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Topics: Adolescent; Adult; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Young Adult | 2010 |
Raltegravir-induced cerebellar ataxia.
Topics: Cerebellar Ataxia; Female; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome | 2010 |
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nitriles; Pyridazines; Pyrimidines; Sequence Alignment | 2011 |
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neuropsychological Tests; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2011 |
SENSE makes us rethink the second-generation nonnucleoside reverse transcriptase inhibitor etravirine's place in HIV-1 treatment.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2011 |
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
Topics: Anti-Retroviral Agents; Aspergillosis; Aspergillus; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles; Voriconazole | 2011 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Child; Controlled Clinical Trials as Topic; Dideoxynucleosides; Drug Approval; Drug Labeling; Female; Growth Hormone-Releasing Hormone; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Infant, Newborn; Male; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2011 |
Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.
Topics: Adult; Female; HIV Infections; HIV-1; Humans; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Treatment Outcome | 2011 |
Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Spain; Treatment Outcome | 2011 |
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.
Topics: Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2011 |
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.
Topics: Adult; Anti-HIV Agents; Antimalarials; Atovaquone; Chemoprevention; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Malaria; Nitriles; Plasma; Proguanil; Pyridazines; Pyrimidines; Saquinavir | 2011 |
Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Gene Expression Regulation, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Phenotype; Pyridazines; Pyrimidines | 2011 |
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles | 2011 |
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Virus Replication | 2011 |
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Treatment Failure; Viral Load; Zidovudine | 2011 |
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Nitriles; Pyridazines; Pyrimidines; Virus Replication | 2011 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation, Missense; Nevirapine; Nitriles; Prevalence; Pyridazines; Pyrimidines | 2011 |
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.
Topics: Anti-HIV Agents; Genotype; HIV Infections; HIV-1; Humans; Linear Models; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2011 |
Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Topics: Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Glucuronosyltransferase; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2011 |
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral | 2012 |
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Typing; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load | 2012 |
A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzodiazepines; Clobazam; Cytochrome P-450 CYP2C9; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Neurotoxicity Syndromes; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2012 |
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides | 2012 |
Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutant Proteins; Mutation, Missense; Nitriles; Portugal; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Failure | 2012 |
Etravirine concentrations in CSF in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Blood; Cerebrospinal Fluid; Chromatography, Liquid; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Middle Aged; Nitriles; Plasma; Pyridazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Tandem Mass Spectrometry; Viral Load | 2012 |
Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Topics: Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Gastrostomy; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium | 2012 |
Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
Topics: Alkynes; Amino Acid Sequence; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV-1; Humans; Molecular Sequence Data; Mozambique; Nevirapine; Nitriles; Proviruses; Pyridazines; Pyrimidines; Sequence Analysis, DNA | 2012 |
Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.
Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Vagina; Virus Replication | 2012 |
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Nitriles; Plasma; Pyridazines; Pyrimidines; Ritonavir; Triazoles | 2012 |
Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genetic Association Studies; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Phenotype; Prognosis; Pyridazines; Pyrimidines; Treatment Outcome | 2012 |
Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US.
Topics: Adolescent; Anti-HIV Agents; Child; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2012 |
[HIV therapy of the next generation. Modern active drugs for long-term treatment].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Long-Term Care; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sulfonamides | 2012 |
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2012 |
Etravirine concentrations in seminal plasma in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Semen; Viral Load | 2013 |
Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
Topics: Amino Acid Sequence; Anti-HIV Agents; Brazil; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Nitriles; Protein Structure, Tertiary; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Zidovudine | 2013 |
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Topics: Adolescent; Adult; Aged; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Models, Statistical; Nitriles; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Pyridazines; Pyrimidines; Switzerland; Tissue Distribution; Young Adult | 2013 |
A probable interaction between warfarin and the antiretroviral TRIO study regimen.
Topics: Anticoagulants; Darunavir; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; International Normalized Ratio; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sulfonamides; Venous Thrombosis; Warfarin | 2012 |
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
Topics: Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Selection, Genetic; Serial Passage; Virus Replication | 2013 |
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles | 2013 |
Etravirine in CSF is highly protein bound.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Cohort Studies; Female; HIV Infections; Humans; Inhibitory Concentration 50; Isotope Labeling; Male; Middle Aged; Nitriles; Plasma; Protein Binding; Proteins; Pyridazines; Pyrimidines; Tandem Mass Spectrometry; Ultracentrifugation | 2013 |
Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.
Topics: Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Pyridazines; Pyrimidines; Sequence Analysis, DNA | 2013 |
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2002 |
One as potent as five.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Viral Load | 2002 |
An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.
Topics: Adult; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Nitriles; Phenotype; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
TMC 125 possibly effective against NNRTI-resistant HIV.
Topics: Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Virus Replication | 2004 |
Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.
Topics: CD4-Positive T-Lymphocytes; Coculture Techniques; Dendritic Cells; Dose-Response Relationship, Drug; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Nitriles; Pyridazines; Pyrimidines; Virus Replication | 2005 |
Report from the 13th retrovirus conference. New data on TMC114 and TMC125.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Sulfonamides; Viral Load | 2006 |
The latest in antiretroviral therapy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles | 2006 |
Anti-HIV agents. The need for etravirine (TMC125).
Topics: HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2007 |
Anti-HIV agents. Etravirine--interactions with some medications.
Topics: Anti-Bacterial Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Nitriles; Piperazines; Purines; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones | 2007 |
Anti-HIV agents. Effectiveness of etravirine in treatment-experienced PHAs.
Topics: CD4 Lymphocyte Count; Female; Health Services Accessibility; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2007 |
Anti-HIV agents. Brain side effects not common with etravirine.
Topics: Brain; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Male; Nitriles; Placebos; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Advances in HIV therapeutics: the 14th CROI.
Topics: Acyclovir; Anti-HIV Agents; Circumcision, Male; Cyclohexanes; Dideoxynucleosides; Drug Interactions; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multicenter Studies as Topic; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Triazoles | 2007 |
Drug resistant HIV.
Topics: Anti-HIV Agents; Chronic Disease; Drug Resistance, Viral; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Technology, Pharmaceutical | 2007 |
Expanded drug access: etravirine (formerly TMC-125).
Topics: Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Topics: Adult; Anti-Retroviral Agents; Area Under Curve; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; RNA, Viral; Sulfonamides; Viral Load | 2007 |
No patient left behind--better treatments for resistant HIV infection.
Topics: Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Viral Load | 2007 |
Report from the XVI International HIV Drug Resistance Workshop.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Lopinavir; Maraviroc; Nitriles; Piperazines; Pyridazines; Pyrimidines; Pyrimidinones; Triazoles | 2007 |
TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.
Topics: Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Prevalence; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2007 |
FDA approves new HIV drug after priority review.
Topics: Administration, Oral; Adult; Double-Blind Method; Drug Approval; Female; HIV Infections; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome | 2008 |
FDA approval: etravirine.
Topics: CD4 Lymphocyte Count; Drug Approval; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; United States; Viral Load | 2008 |
[New drugs for HIV infection].
Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2008 |
Tests on new NNRTI show strong potency.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HIV Infections; Humans; Nitriles; Placebos; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2002 |
TMC125 shows promise.
Topics: Anti-HIV Agents; Child; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
Researchers explore new anti-HIV agents.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclic N-Oxides; Drugs, Investigational; Enfuvirtide; Furans; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Oximes; Peptide Fragments; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2002 |
Drugs in development.
Topics: Adenine; Anti-HIV Agents; Clinical Trials as Topic; Cyclic N-Oxides; HIV Infections; Humans; Nitriles; Organophosphonates; Organophosphorus Compounds; Oximes; Piperidines; Pyridazines; Pyridines; Pyrimidines; Tenofovir | 2002 |